 So thank you so much everyone. Good morning. The first things about this study came in my mind. It's a song that say in this great future We cannot forget the past. It's a quite famous song and it's exactly the principle on why we look at this study. HFV has been changing so much in the last 10 years in terms of drugs availability, monotherapy, triple therapy, viral load, point-of-care, CD4 count. But we felt that it was nice, probably a good exercise for us to have a look about what is our achievement in 10 years times, what has been done, what is the main outcome and what could be a good lesson learned for the future of our operation as well. So we decided to have the best way to do that could be probably a description of what is clinical, immunological and virological characteristics of the HFV cohort patient in Myanmar where we are working with MSF-ZWIS. Very briefly about Myanmar. It's a concentrated epidemics as most of the country in Southeast region and the highest prevalence it's in people injecting drugs, men having sex with men and female sex worker. In the general population, it's just zero point five. MSF has been working next year will be 25 years in Myanmar, but since 2004 it's collaborating with the MOH and especially with the national AIDS program. There are two sections. There is MSF Switzerland and MSF Holland. The colleague from MSF Holland will present later on. While we as OCG, we are focused mostly in the southern region in the Tanitari division especially that is on the border with Thailand. And specifically we have a clinic in Dawey where we are treating HIV, TB and recently also hepatitis C and any kind of co-infection. So when we decided to have this rationale, we also noticed that there was not much literature available, especially in the long-term outcomes of ART project in low-middle income country obviously and especially even less in Myanmar. So as I said, we would think that we thought that actually describing the clinical immunology and biological through WHO staging, CD4 count and viral load would give us some kind of information and direction about outcome, but also way forward. For the one they are not familiar with the MSF family, we use a baseline characteristic from FUSHA database. FUSHA database is a software where you have most of the information related with HIV and TB patients. We decided to get people from August 2004-2006 until September 2015 and we obviously received the ethical approval from both MSF board and ministry of LTMMR. The numbers have what normally give the best answer to everything and in this case we have 615 people identifying this range of times of which almost 70% are still active in care or alive in care. And as you can notice, we have a big prevalence, a big average of that, number of that. Later on we will explain much better why there is some specific reason why it's so high. From the 68%, 480 patients are still in care and just, not just, but 385, they decided to participate in the study. Not all of them because obviously we request the patient consensus. So in terms of profile, as you can see, there is no big difference in men and women. 10-11% is not a big discrepancy, I would say. And especially we are talking about adults. 20 to 49 years it's the vast majority of our patients. The difference between men and female came when we are looking at number of deaths and loss of follow-up. It's almost, male are accountable for almost 70% of the all deaths and the loss of follow-up from which we can expect that included probably also some that. This chart probably clarifies a bit better why we have this 25%. As you can notice at WHO staging, most of the active care, when they arrived, they were at stage 3 and 4. This means they arrived late at our clinic. That means that they access health care when they were very sick. And this is also reflecting number of deaths. 88% of the deaths happen when people were on this stage. This is, again, explain a bit better because even if you have a very good doctor, even if you have the drugs available that is not always the case, manage this kind of patient, it's extremely complicated. The same is for loss of follow-up. Again, as before I think it's possible that around this 28 cases, 80%, there is some death that has been not recorded. And as late presenter profile, we have also the CD4 that is less than 100 for 31% of the court. So I think we have a clear idea about how is the profile adult, probably male has more problem. Last year a colleague Janet also identified fishermen as key population, especially for the context of the way, and late presenter. People are arriving very late. Sorry. The last point I included as a kind of limitation of the study because for almost 36% of the patient, we didn't have the information. That was the time of 2004, I hope. And I'm sure that in 10 years we improve a bit the MNE system, but it's still relevant to mention. So what are the good news? The great important news for me is 96.8% of patients have undetectable viral load. This is an amazing result. It's in line with WHO guideline of 1990 target, but especially I think it's very important not for MSF specifically, but mostly for the life of the patient. It clearly demonstrates how it's possible to run a project in the low middle income country on an HIV program and having a significant impact on the life of the patient. The same it's about CD4 count, 548 cells. It's comparing with the beginning. It's a great achievement. Second line is not that high, but obviously still underlined the fact that for the future we still need to consider second and probably third line will become more and more important in our project. And what surprised me more, to be honest, is the mutation of resistance. We have just four cases of mutation in 10 years time. It's such a big cohort. I think it's a good result. The bad news on the other hand, it's more tidy. Of that 25% that we saw at the beginning, 53% die in the first year. Again, it's a logical consequence of the late presenter profile that we discussed before, but definitely it's something that we need to address. At that time again, in 2004 probably there was no awareness, discrimination, and stigmatization was an issue to access healthcare. The situation at the moment is getting a bit better, but we are not really improved that much. But definitely it's something that we need to keep in consideration when we are designing an HIV intervention. Just for the description, not surprisingly and unfortunately, B is still remain very high with morbidity. It's almost 40% of our patients that have high burden. And I want to stress also hepatitis C, especially in Myanmar. It's a context where prevalence is pretty high and in our cohort it's more than 12%. We have the chance as well to treat now, fortunately, the disease. So to conclude this part, I think it's very good. We can be happy or satisfied with 96% of undetectable viral load. We definitely need to work more on more tidy rate, especially in the first year. And comorbidities still remain a problem in the service that we need to move more and more to the integrated service. And especially comorbidities, we decided to get just as quickly more detail on Cryptococcal meningitis, still in the same context, still in the same clinic, still the same team working on that. Why Cryptococcal meningitis specifically? Because there is high mortality. Because number of cases in Southeast Asia, it's pretty high. It's the second highest after Southern African region. We're talking about under 35,000 cases per year according to CDC. And of course from Myanmar, we don't have much or no data. And the analysis was more or less conducted in the same way. It's retrospective using FUSHA and also patient file to see the characteristics of this population. Although it's slightly different because we counted in terms of procedure, we counted from November till November, 2004 till November, 2050, the profile is more or less the same. As again, with no big surprise, we have WHO staging 3 and 4, 90 percent, CD4 count lower than 185 percent, and mostly male. We have the chance also to make diagnosis both in serum and in cerebral spinal fluid. These are the results. Very simple. I try to keep as simple as possible. As you see, 80 percent, it's between transfer out and that and loss of follow up. And then you see there are two pieces of cake that looks exactly the same. It's number of dead and people active in care. I swear it's not a mistake. We counted three times with epidemiologists, but it's exactly the same number. This means that mortality, it's pretty still very high for this disease. And we need to address this problem in our HIV court. What we try to do it, it's to improve the treatment first. Dianosis is more or less okay. But in March 2014, we introduced amphotericine B together with frugonazole. Since now, nine patients, only nine patients, fortunately, they've been treated with no side effects. We know that there is a lot of resistance in using amphotericine in clinic, but we have experience that it's possible to manage also at very in remote area. So the conclusion is like we finally be able to show some result and the high mortality of cryptococcal. There is, again, high mortality in our cohort. And we look forward to have an implementation of amphotericine B also in lower service in clinic. I want to thank the team, the whole team,